1Q23 Performance Overview

RETAIL (PHARMACY) BUSINESS OPERATING PERFORMANCE OVERVIEW ☐ REVENUE DEVELOPMENT +14.1% -0.3% 199 198 EBITDA¹ DEVELOPMENT +56.7% -0.5% GEORGIA CAPITAL 21 21 13 1Q21 1Q22 1Q23 1Q21 1Q22 1Q23 RETAIL (PHARMACY) KEY DRIVERS 1Q23 revenue and EBITDA were largely flat, notwithstanding a) a significant decrease in product prices, due to GEL's appreciation against foreign currencies and b) the negative impact of the External Reference Pricing model, which introduces a maximum retail price on targeted prescription medicines that are financed by the State. EBITDA was further impacted by an increase in operating expenses in line with the overall inflation and the continuing expansion of the business (added 19 pharmacies y-o-y as of 31-Mar-23). The y-o-y decrease in the same store revenue growth rate in 1Q23 is attributable to GEL's appreciation against foreign currencies. GEL MILLION 174 KEY OPERATING HIGHLIGHTS Georgia Capital PLC | 1. Excluding IFRS 16. 1Q22 VS. 1Q23 Same store revenue growth 12.5% -3.2% Number of bills issued (mln) 7.6 Average bill size 19.3 Change y-o-y -15.7ppts 7.6 +0.8% 19.4 +0.3% 62 52

View entire presentation